contractor articles (340)
Active Articles:
None to display.Retired Articles:
A48434: 55876: Implanted Fiducial Markers—Coding and Billing GuidelinesA48436: Adjustment of Gastric Band after Laparoscopic Gastric Banding Procedure
A48437: Administration of Certain Biological Response Modifiers
A48438: Allowance for Procedure code R0070
A48439: Angiojet Thrombolytic Therapy 37799, 37184-37188
A48440: Are You Getting the Correct Reimbursement when Billing for Unclassified Drugs Using HCPCS Codes J3490, J3590, or J9999?
A48442: Billing Compounded Drugs, Service Date on/after March 20, 2006
A48443: Billing Compounded Drugs, Service Date prior to March 20, 2006
A48444: Billing Compounded Drugs, Update
A48448: Cardiac Computed Tomography and Computed Tomography Coronary Angiography 0144T-0151T - Emerging Technology
A48449: Claim Denials of New Mammography Codes
A48454: Descemet’s Stripping Endothelial Keratoplasty—Coding and Billing
A48455: Electrocardiogram, 64 leads or greater—Coding and Billing
A48456: Emergency Department Services, Consultations, and Critical Care Visits
A48457: Humanitarian Use Device and Humanitarian Device Exemptions
A48458: Intracoronary (Intravascular) Brachytherapy
A48459: Intravenous Emend® (Fosaprepitant)
A48460: Intravitreal Bevacizumab (Avastin®) for Neovascular Age-Related Macular Degeneration - Update
A48461: J0881: Erythropoiesis Stimulating Agents–Clarification on correct modifier use
A48462: J1440: G-CSF (Filgrastim, Neupogen®)—Clarification
A48463: J2357: Omalizumab (Xolair) administration and 96401 -- clarification of correct billing
A48464: J2505: Clarification on correct administration of Neupogen and Neulasta
A48465: J3490: Triesence™ (triamcinolone acetonide injectable suspension)
A48466: J9025: VIDAZA and administration code 96401 - clarification of correct billing
A48467: Local Anesthetic Agents Used for Anesthesia or Therapeutic Injection
A48468: Lucentis (ranibizumab injection) for Neovascular Age-Related Macular Degeneration
A48470: New Requirements for Chiropractic Billing of Active/Corrective Treatment and Maintenance Therapy
A48471: Operative Tissue Ablation and Reconstruction of Atria (Maze Procedure)
A48472: Percutaneous tibial nerve stimulation (PTNS) for voiding dysfunction
A48473: PROVIDERS BILLING FOR CPT CODE 99211
A48474: Quantitative Sensory Testing (QST) - 0107T
A48475: Real time Outpatient Cardiac Telemetry Monitoring and Analysis
A48476: Reporting Critical Care Services
A48477: Requirements for the Payment of Medicare Claims - A Selection of Some Important Criteria
A48478: Stereotactic Radiosurgery and Stereotactic Radiotherapy – Correction to Article
A48479: SURGICAL DIAGNOSTIC PROCEDURES REQUIRING MODIFIER TC WHEN BILLED BY AN AMBULATORY SURGICAL CENTER
A48480: Update to Information Regarding Medicare Payment and Coding for Drugs and Biologicals
A48481: Uterine Artery Embolization
A48482: Vagal Nerve Stimulation for Intractable Depression
A48483: Vagal Nerve Stimulation for Seizures and Resistant Depression
A48484: Vertebral Fracture Assessment–CPT Code 76077—Revised Article
A48485: Verteporfin - Billing Clarification
A48486: Vitagel TM Surgical Hemostat
A48702: Emerging Diagnostic Technology – NC-stat System, NeuroMetrix® - Revision of Coding Instructions
A48712: Intravitreal bevacizumab (Avastin®) for neovascular age -- related macular degeneration -- coding & billing update
A48714: The Urgent® PC neuromodulator (UPC) for percutaneous tibial nerve stimulation (PTNS) for voiding dysfunction
A48849: Addition to the self-administered injectable drug (SAD) list
A48943: NCSVCS: The list of Medicare noncovered services revision to the LCD
A48947: J9263: Oxaliplatin (Eloxatin®) revision to the LCD
A48953: J3487: Zoledronic acid revision to the LCD
A48954: J2505: Pegfilgrastim (Neulasta™) revision to the LCD
A48959: J9045: Carboplatin (Paraplatin®, Paraplatin-AQ®) revision to the LCD
A48960: A9600: Metastron c strontium 89 chloride revision to the LCD
A49019: Updated Medicare coverage for off-label use of anti-cancer drugs
A49049: PET bone imaging and sodium fluoride F-18
A49051: Addition to the self-administered injectable drug (SAD) list
A49055: BOTULINUMTOXINS: Botulinum toxins revision to the LCD
A49084: SKINSUB Skin substitutes revision to the LCD
A49086: 95805 Polysomnography and sleep testing new LCD
A49092: J0881 Erythropoiesis stimulating agents revision to the LCD
A49096: Intravitreal bevacizumab (Avastin®) new LCD
A49098: A0425 Non-emergency ground ambulance services new LCD
A49101: IDTF Independent diagnostic testing facility revision to the LCD
A49103: NCSVCS The list of Medicare noncovered services revision to the LCD
A49105: J9305 Pemetrexed revision to the LCD
A49165: Billing for drugs usually administered orally
A49167: Physician’s order for clinical laboratory services and diagnostic procedures
A49170: THERSVCS Therapy and rehabilitation services revision to the LCD
A49186: J9999: Plerixafor (MOZOBIL™) clarification of administration
A49188: J3487: Zoledronic acid revision to the LCD
A49201: J9350: Topotecan hydrochloride (Hycamtin®) revision to the LCD
A49256: J0740: Ganciclovir and cidofovir revision to the LCD
A49257: NCSVCS: The list of Medicare noncovered services revision to the LCD
A49259: J9999: Plerixafor (MOZOBIL™) revision to article
A49261: 0197T/77499: Calypso® 4D localization system TM
A49264: 95805: Polysomnography and sleep testing extended date of accreditation
A49266: NCSVCS: The list of Medicare noncovered services revision to the LCD
A49268: SKINSUB: Skin substitutes revision to the LCD
A49316: 95805: Polysomnography and sleep testing revision to the LCD
A49317: J2778: Ranibizumab (Lucentis®) article clarification
A49362: THERSVCS: Therapy and rehabilitation services revision to the LCD
A49363: NCSVCS: The list of Medicare noncovered Services revision to the LCD
A49433: J9212: Interferon revision to the LCD
A49436: G0108: Diabetes outpatient self-management training revision to the LCD
A49470: Administration of intravenous antibiotics via external infusion pump
A49473: J2503: Macugen® (pegaptanib sodium injection) revision to the LCD
A49474: Signature requirements clarification
A49478: Intravitreal bevacizumab (Avastin®) revision to the LCD
A49480: J3487: Zoledronic acid revision to the LCD
A49483: Appropriate use of modifier 50 for paravertebral/facet joint injection services
A49604: J9055: Cetuximab (Erbitux®) revision to the LCD
A49606: Billing and coding information for prostate biopsies
A49608: OOS: Outpatient observation services retired LCD
A49610: PULMDIAGSVCS: Pulmonary diagnostic services revision to the LCD
A49612: J9213: Interferon, alfa-2a (Roferon®-A) retired LCD
A49638: 95004: Allergy tests revision to the LCD
A49644: G0430: Qualitative drug screening new LCD
A49645: G0179: Physician certification and recertification of home health services revision to the LCD
A49649: BOTULINUM TOXINS: Botulinum toxins revision to the LCD
A49652: J9025: Azacitidine (Vidaza®) revision to the LCD
A49653: IDTF: Independent diagnostic testing facility (IDTF) revision to the LCD
A49658: Intravitreal Bevacizumab (Avastin®) revision to the LCD
A49737: Billing and coding of synvisc and synvisc-one
A49742: J9045: Carboplatin (Paraplatin®, Paraplatin-AQ®) revision to the LCD
A49747: J3487: Zoledronic acid revision to the LCD
A49748: THERSVCS: Therapy and rehabilitation services revision to the LCD
A49764: Claims for procedure code 20610 denied in error
A49765: Billing compounded drugs for services on and after March 20, 2006
A49767: Claims for procedure code J7325 denied in error
A49783: SKINSUB: Skin substitutes revision to the LCD
A49789: J9305: Pemetrexed revision to the LCD
A49813: Self-administered drug (SAD) list
A49860: J3420: Vitamin B12 injections - revision to the LCD
A49861: J9310: Rituximab (Rituxan®) - revision to the LCD
A49869: J2796: Romiplostim (Nplate ®) - new LCD
A49871: J2562: Plerixafor (Mozobil ®) - new LCD
A49872: 93980: Duplex scan for erectile dysfunction – new LCD
A49878: NCSVCS: The list of Medicare noncovered services - revision to the LCD
A49879: G0430: Qualitative drug screening revision to the LCD
A49904: NCSVCS: The list of Medicare noncovered services - revision to the LCD
A49941: J1950: Luteinizing hormone-releasing hormone (LHRH) analogs- revision to the LCD
A49969: J2503: Macugen (pegaptanib sodium injection) – revision to the LCD
A49970: 95805: Polysomnography and Sleep Testing-revision to the LCD
A49973: Xiaflex™ (collagenase clostridium histolyticum) - coding instructions
A49975: Medicare coverage of Qutenza® (capsaicin) 8% patch for treatment of post-herpetic neuralgia
A49994: G0430: Qualitative drug screening revision to the LCD
A50018: NCSVCS: The list of Medicare noncovered services - revision to the LCD
A50045: J7187: Hemophilia clotting factors - revision to the LCD
A50048: SKINSUB: Skin substitutes – revision to the LCD
A50053: G0430: Qualitative drug screening – revision to the LCD
A50055: J1950: Luteinizing hormone-releasing hormone (LHRH) analogs – revision to the LCD
A50063: NCSVCS: The list of Medicare noncovered services – revision to the LCD
A50099: NCSVCS: The list of Medicare noncovered services – revision to the LCD
A50101: 95990: Implantable infusion pump for the treatment of chronic intractable pain – new LCD
A50103: Qutenza ®: Qutenza ® (capsaicin) 8% patch – new LCD
A50143: J2778: Ranibizumab (Lucentis ®) – revision to the LCD
A50371: J1459: Intravenous immune globulin – revision to the LCD
A50409: J9355: Trastuzumab (Herceptin®) - revision to the LCD
A50497: 95921: Autonomic function tests – new LCD
A50501: HAE: Selective treatment for HAE with Cinryze ™, Berinert ®, and ecallantide – new LCD
A50525: J9201: Gemcitabine (Gemzar®) revision to the LCD
A50572: G0431: Qualitative drug screening revision to the LCD
A50576: J0470: Chelation therapy revision to the LCD
A50579: NCSVCS: Noncovered services revision to the LCD
A50636: J9010: Alemtuzumab (Campath®) revision to the LCD
A50648: J9181: Etoposide (Etopophos®, Toposar®, Vepesid®, VP-16) revision to the LCD
A50685: J9395: Fulvestrant (Faslodex®) revision to the LCD
A50713: J9055: Cetuximab (Erbitux ®) revision to the LCD
A50779: BOTULINUM TOXINS: Botulinum toxins revision to the LCD
A50788: SKINSUB: Skin substitutes revision to the LCD
A50800: G0431: Qualitative drug screening revision to the LCD coding guidelines
A50804: J1459: Intravenous immune globulin revision to the LCD
A50884: J0600: Injection, edetate calcium disodium, up to 1000 mg
A50886: J1740: Boniva ® (ibandronate sodium) injection program vulnerability
A50887: 96521: Refilling and maintenance of portable pump
A50894: IDTF: Independent diagnostic testing facility (IDTF) - revision to the LCD
A50895: NCSVCS: Noncovered services revision to the LCD
A50912: J9310: Rituximab (Rituxan®) revision to the LCD
A50928: BOTULINUM TOXINS: Botulinum toxins revision to the LCD
A50933: G0431: Qualitative drug screening revision to the LCD coding guidelines
A50934: J7308: Topical photosensitizers used with PDT for actinic keratoses and certain skin cancers new LCD
A50938: Computed tomography (CT) scans revisions to LCDs
A50939: Magnetic resonance imaging (MRI) revisions to LCDs
A50940: NCSVCS: Noncovered services revision to the LCD
A50944: Self-administered drug (SAD) list
A50956: Single and dual chamber cardiac pacemakers draft LCD
A50958: 90935-90937: Hemodialysis for treatment of schizophrenia National Coverage Determination
A50961: NCSVCS: The list of Medicare noncovered services - revision to the LCD
A50962: Widespread probe review: Autonomic function testing 95921
A50963: 84295; Serum sodium and 82435; Chloride blood: update to previous billing instructions,
A50966: Clarification of modifier use when billing more than one diagnostic test for same procedure on same date of service
A50969: J3490/C9272: Prolia ™ (denosumab)
A50970: J3490/C9272: Xgeva ™ (denosumab)
A50973: 37205: Non-coronary vascular stents - draft LCD article clarification
A50990: Self-administered drug (SAD) list Part B: J1559
A51024: Physician billed rehabilitation services
A51172: Widespread probe review: Cefepime HCL J0692
A51225: Intravitreal bevacizumab (Avastin®) revision to the LCD
A51227: Clarification of a qualified physician statement revisions to the LCDs
A51230: J7184: Hemophilia clotting factors revision to the LCD
A51232: J1459: Intravenous immune globulin revision to the LCD
A51234: J2778: Ranibizumab (Lucentis®) revision to the LCD
A51236: NCSVCS: Noncovered services revision to the LCD
A51241: J9310: Rituximab (Rituxan®) revision to the LCD
A51244: SKINSUB: Skin substitutes revision to the LCD
A51245: IDTF: Independent diagnostic testing facility (IDTF) coding guidelines revision
A51279: NCSVCS: Noncovered services revision to the LCD
A51285: J7187: Hemophilia clotting factors retirement of coding guidelines
A51295: J3095: Vibativ (telavancin) clarification on billing
A51330: NCSVCS: Noncovered services revision to the LCD
A51362: J0881: Erythropoiesis stimulating agents revision to LCD
A51380: DRUGSANDBIOLOGICALS: Label and off-label coverage of outpatient drugs and biologicals new LCD
A51381: J1740: Bisphosphonates (intravenous [IV]) and monoclonal antibodies in the treatment of osteoporosis and their other indications new LCD
A51385: J3487: Zoledronic Acid retired LCD
A51399: J1740: Bisphosphonates (intravenous [IV]) and monoclonal antibodies in the treatment of osteoporosis and their other indications – clarification to the LCD
A51423: Magnetic resonance imaging (MRI) revisions to the LCDs (Part A)
A51434: IDTF: Independent diagnostic testing facility (IDTF) - coding guidelines revision
A51455: Chemotherapy and non-chemotherapy injection and infusion services
A51457: Part B 3D rendering with interpretation and reporting of imaging studies
A51473: J9206: Irinotecan (Camptosar®) revision to the LCD
A51479: J9041: Bortezomib (Velcade®) revision to the LCD
A51481: Self-administered drug (SAD) list Part B: J0630
A51493: SKINSUB: Skin substitutes revision to the LCD
A51494: J9201: Gemcitabine (Gemzar®) revision to the LCD
A51496: J9305: Pemetrexed revision to the LCD
A51555: NCSVCS: Noncovered services – revision to the LCD
A51632: J9263: Oxaliplatin (Eloxatin®) revision to the LCD
A51647: Claims for CPT code 36415 or HCPCS codes P9612/P9615 denied in error
A51708: NCSVCS: Noncovered Services – revision to the LCD
A51710: J2796: Romiplostim (Nplate®) revision to the LCD
A51720: Multiple local coverage determinations (LCDs) being retired
A51722: IDTF: Independent diagnostic testing facility (IDTF) revision to the LCD “Coding Guidelines” attachment
A51741: Self-administered drug (SAD) list Part B: J3490/J3590/C9399/J1324
A51778: J9001: Doxorubicin, liposomal (Doxil) revision to the LCD
A51779: THERSVCS: Therapy and rehabilitation services – revision to the LCD
A51780: BOTULINUM TOXINS: Botulinum toxins – revision to the LCD
A51781: J9041: Bortezomib (Velcade®) revision to the LCD
A51795: J9033: Bendamustine hydrochloride (Treanda®) – new LCD
A51797: NCSVCS: Noncovered services revision to the LCD
A51852: Self-administered drug (SAD) list Part B: J3490/J3590/C9399
A51857: IDTF: Independent diagnostic testing facility (IDTF) revision to the LCD
A51859: J9310: Rituximab (Rituxan®) revision to the LCD
A51863: Single and dual chamber cardiac pacemakers
A51869: J9001: Doxorubicin liposomal (Doxil) revision to the LCD
A51876: Clarification of ‘Appropriate use of assistant at surgery modifiers and payment indicators’ article published February 2, 2012
A51877: Appropriate use of assistant at surgery modifiers and payment indicators
A51878: J0881: Erythropoiesis stimulating agents revision to the LCD
A51881: SKINSUB: Skin substitutes revision to the LCD
A51884: NCSVCS: Noncovered services revision to the LCD
A51885: NCSVCS: Noncovered services revision to delete HCPCS code C9732 and replace with CPT® code 0308T, and delete CPT® code 66999
A51948: IMT: Implantable miniature telescope (IMT) new LCD
A51949: NCSVCS: Noncovered services revision to the LCD
A51950: THERSVCSPHYSICIAN: Therapy services billed by physicians/nonphysician practitioners new LCD
A51969: J9055: Cetuximab (Erbitux®) revision to the LCD
A51972: J2778: Ranibizumab (Lucentis®) revision to the LCD
A51987: Clarification of the proper use and billing of adenosine injections
A51988: THERSVCS: Therapy and rehabilitation services revision to the LCD
A52020: J2778: Ranibizumab (Lucentis ®) revision to the LCD
A52022: BOTULINUM TOXINS: Botulinum toxins – revision to the LCD
A52056: TESTOPEL: Testosterone pellets (Testopel®) – new LCD
A52063: ANCSVCS: Noncovered services – revision to the LCD
A52064: NCSVCS: Noncovered services 0101T revision to LCD
A52071: Self-administered drug (SAD) list Part B: J1744/J2212
A52074: J9263: Oxaliplatin (Eloxatin®) revision to the LCD
A52098: NCSVCS: Noncovered services revision to the LCD
A52127: J9181: Etoposide (Etopophos®, Toposar®, Vepesid®, VP-16) revision to the LCD
A52170: IDTF: Independent diagnostic testing facility (IDTF) revision to the LCD “Coding Guidelines” attachment
A52195: NCSVCS: Noncovered Services revision to the LCD
A52196: NCSVCS: Noncovered Services quarterly revision to the LCD
A52201: Independent diagnostic testing facility (IDTF) revision to the LCD ‘Coding Guidelines’ attachment
A52214: Self-administered drug (SAD) list Part B: J3490/J3590/C9399
A52219: BOTULINUMTOXINS: Botulinum toxins revision to the LCD
A52223: SKINSUBSTITUTES: Application of bioengineered skin substitutes for treatment of diabetic and venous stasis ulcers of the lower extremities draft LCD
A52248: Minimum criteria for reimbursement of diagnostic ultrasound tests
A52276: Noncovered services revision to the Part B LCD
A52315: Independent diagnostic testing facility (IDTF) revision to the Part B LCD
A52321: Noncovered services revision to the Part B LCD
A52347: Noncovered services revision to the Part B LCD
A52357: Draft Sources of Information and Basis for Decision: Noncovered Services LCD
A52404: Draft - Sources of Information and Basis for Decision Noncovered Services LCD
A52506: Independent diagnostic testing facility (IDTF) revision to the Part B LCD “Coding Guidelines” attachment
A52552: Independent diagnostic testing facility (IDTF) revision to the Part B LCD “Coding Guidelines” attachment
A52554: Polysomnography and sleep testing revision to the Part B LCD
A52674: Surgical management of morbid obesity revision to the Part B LCD
A52744: Noncovered services revision to the Part B LCD
A52781: Self-administered drug (SAD) list Part B: J3590/C9399/Q3026
A53150: Independent diagnostic testing facility (IDTF) revision to the Part B “Coding Guidelines” attachment
A53160: Noncovered services revision to the Part B LCD